When: Breakout close above $94.74 on volume >10M with follow-through

Then: Add position on confirmed breakout

When: Breakout retest holding as support OR flush to $88-$90 holding 200 SMA

Then: Reserve tranche for retest or flush tier

WAIT FOR PULLBACK TO $91.70-$92.30 OR CONFIRMED BREAKOUT ABOVE $94.74 ON VOLUME > 10M; IF INITIATING, REDUCE TRANCHE ONE TO TOKEN 25 BASIS POINTS RATHER THAN FULL HALF-WEIGHT

• MACD crossed below signal line with histogram flipped negative and oscillator pulled back 35% from peak; compares current setup to prior failures at upper Bollinger Band with negative histogram that tested middle band, lower band, and 200 SMA
• Volume of 8.63 million on breakout attempt day (stock tagged $94.74, closed $94.17) is below 10 million threshold and September 1st print of 18.8 million; half-position commitment without volume confirmation is still unconfirmed breakout
• Fifty-seven percent earnings recovery from restructuring creates disproportionate downside risk if any slippage occurs in execution, FX headwinds, or China VBP pricing materializes
• Stock sitting on upper Bollinger Band with RSI recently off 75 overbought; ATR expanded from $1.85 to $2.28 indicating rising volatility; resistance at $96/$98/$100, major support (lower Bollinger) at $89.07
• Stop at $89.50 is barely a buffer beyond normal noise; ATR $2.28 plus 1.5 standard deviation adverse move puts stop-exit at $89.78; 2 ATR move reaches $89.61; normal volatility expansion would test the stop
• Position size of 1.25-1.5x benchmark represents roughly 60-75 basis points of portfolio risk; 4-5% adverse move in single defensive name is real drawdown; MDT correlations to other defensive healthcare compounders likely high in macro shock
• Macro green-light already priced in (93% no-cut pricing, 6% recession odds); Barron's dividend aristocrat screen, Motley Fool four-reasons-to-buy, RBC defining-step call suggest crowded positioning with no marginal buyers left
• Confluence zone at $91.70-$92.30 is defined entry with defined stop (strategy), not chasing moving target; rising EMAs are a feature not a bug in uptrend defining higher low; missing move to $96 costs nothing but stop-out at $89.50 costs 4-5%

→ vs aggressive: MACD positive trend regime at 1.73 misuses cyclical capitulation low ($73 in May-June) as comparison anchor; relevant comparison is prior upper Bollinger Band + negative MACD histogram setups that failed and tested middle band, lower band, and 200 SMA

→ vs aggressive: Volume normalization of 8.63 million is wrong comparison; breakout attempt day should be compared to prior breakout volumes like September 1st's 18.8 million, not recent average; committing half position without plan's explicit volume confirmation defeats staging discipline

→ vs aggressive: Rising EMAs are feature not bug in uptrend; they define the higher low that trader's plan explicitly calls for; waiting for pullback to dynamic support is plan working as designed, not chasing moving target

→ vs aggressive: Normalizing 57% earnings recovery as defensible interpretation glosses over that 57% of forward multiple's earnings power depends on flawless execution through fiscal 2027; any disappointment hits disproportionately

→ vs aggressive: 93% no-cut pricing and 6% recession odds represent crowded positioning already in price; if anything disappoints (hawkish Fed, recession probability ticks to 8%, cardiac ablation deceleration from 29.5% to 15%), stock drops hard with no marginal buyers left

→ vs aggressive: Stop at $89.50 calibrated for perfect conditions; ATR $2.28 plus 1.5 standard deviation adverse move reaches $89.78; a generic 1% risk-off open tomorrow stops out the position; 60-75 bps portfolio risk is real drawdown if this is meaningful allocation

→ vs aggressive: Position sizing at 1.25-1.5x benchmark with half-position still represents 60-75 bps portfolio risk; diversification doesn't help if correlations to other defensive healthcare compounders are high in macro shock

BUY with reduced Tranche 1 (25-30% of target overweight) at 94, stop at 89.50; Tranche 2 (30-35%) conditional on pullback to 91.70-92.30 or breakout above 94.74 with volume above 10 million; Tranche 3 (30-35%) on breakout retest or flush to 88-90 holding 200 SMA

• BUY is the correct directional call given strong fundamentals, accelerating revenue, discount valuation at forward P/E of 14.7, and 3% dividend yield
• MACD momentum roll-over is genuine concern with signal line at 1.85 and negative histogram
• Reduce Tranche 1 from half-weight to 25-30% of target overweight to reduce immediate risk at resistance
• Volume of 8.6 million is insufficient for full conviction but doesn't invalidate half-position starter
• Confluence zone at 91.73-92.30 (Bollinger middle, 10 EMA, VWAP) is a defined level with defined stop, not chasing a moving target
• Stop at 89.50 is too tight; ATR is 2.28 and volatility events of 2-2.5 ATR could test the stop on macro tape shifts
• Forward EPS of 6.40 already incorporates raised FY27 guidance post Q1 beat-and-raise, but bar is now high and in-line quarters will disappoint
• Crowding concern is real but not a dealbreaker at 14.7 P/E with improving fundamentals; consensus can persist for quarters
• Macro is supportive but consensus, not a catalyst; 93% no-cut probability is price of admission, not an edge
• Cap full overweight at 1.0-1.1x benchmark to manage concentration risk given healthcare policy, China VBP, FX, and litigation exposures
• If stopped out at 89.50, define re-entry at 87-88 or wait for fresh base above 90; no revenge re-entry

→ vs aggressive: MACD argument is weakest part of pitch; signal line at 1.85 and negative histogram is definition of momentum roll-over, not positive trend confirmation

→ vs aggressive: Stop at 89.50 is too tight for a defensive compounder; ATR is 2.28 and a 2-2.5 ATR volatility event puts stop at risk on routine macro shifts

→ vs aggressive: Crowding at 14.7 P/E with accelerating fundamentals is consensus, not a sell signal; crowded at stretched valuation would be different

→ vs conservative: Pure patience has opportunity cost; if MDT breaks out cleanly to 100, conservative is sitting in cash watching a 15-dollar move in a name where thesis was correct

→ vs conservative: Don't skip Tranche 1 entirely; fundamentals genuinely support a starter position even if technical entry is extended